StreetAlpha.app
Home › Stocks › SYRE

Spyre Therapeutics, Inc. (SYRE)

Healthcare
$93.47
▼ −4.26%
LAST CLOSE · NOV 20

Spyre Therapeutics develops antibody drugs for inflammatory bowel disease and rheumatic conditions. It last closed at $93.47 on Nov 20, down 4.26% on the day. The next earnings report for SYRE is expected around Thu, Feb 18, 2027, after the close. Over its last 8 reports the stock moved an average of 6.2% the session after earnings. Over the last 12 months SYRE insiders bought $0 of stock on the open market and sold $441.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is SYRE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SYRE.

Key Stats

Fiscal 2025
Results
Revenue
$0
Net income
−$155.2M
Valuation
Market cap
$8.9B
95.0M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$82.7M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
95.0M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.7M$18.7MFY2021FY2022: $2.3M$2.3MFY2022FY2023: $886K$886KFY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From SYRE's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 3).

Next report
Feb 18
Estimated date · After the close
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How SYRE moved after its last 8 reports
Average move the session after a report ±6.2%
Nov 3, 2026After the close−0.2%
Aug 4, 2026After the close−0.6%
Apr 13, 2026After the close+1.2%
Feb 19, 2026After the close+14.3%
Oct 14, 2025Time not announced+11.0%
Aug 5, 2025After the close−5.4%
May 8, 2025After the close+9.6%
Feb 27, 2025After the close+7.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SYREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SYRE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SYRE

Technical Analysis

SYRE · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 17) at $92.92, and the nearest resistance the swing high (Oct 21) at $95.17.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$110.6452 week high+18.4%
$99.7220 day average+6.7%
$97.61Pivot R1+4.4%
$95.42Pivot+2.1%
$95.19100 day average+1.8%
$95.17Swing high (Oct 21)+1.8%
$93.47Last close
$92.92Swing low (Nov 17)−0.6%
$92.2850 day average−1.3%
$91.27Pivot S1−2.4%
$78.28200 day average−16.3%
$23.0152 week low−75.4%
Indicators
RSI (14)46.18Middle of its rangeNeutral
MACD1.70Below its signal lineBearish
Stochastic26.6Middle of its rangeNeutral
ADX (14)14.8No clear trend
Williams %R-96.1Oversold below −80, overbought above −20Oversold
CCI (20)-85.9Oversold below −100, overbought above 100Neutral
Rate of change−10.0%Change over 10 sessionsBearish
ATR (14)$5.72Typical daily range, 6.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for SYRE

What happened before

See how SYRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SYRE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SYRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SYREHow many large options trades hit SYRE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SYRE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲188 buying vs 121 selling
  • ▲Held by funds +6.1 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding286266+7.5%
In funds' top 101112−8.3%
Held by funds107.0%100.9%+6.1 pts
New / increased66 / 12289 / 102−1.6%
Reduced / sold out76 / 4556 / 22+55.1%
Put/call ratio–6.95–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SYRE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SYRE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$441.9M30 sales · 7 insiders
9% of the selling was under pre-arranged trading plans.
2025-12 sold $435K2026-01 sold $460K2026-02 sold $492K2026-03 sold $734K2026-04 sold $1.5M2026-05 sold $13.5M2026-06 sold $405.2M2026-07 sold $2.7M2026-08 sold $4.6M2026-09 sold $6.1M2026-10 sold $6.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 1Scott L BurrowsCFOSale plan25,000$90.47$2.3M
Oct 1Cameron TurtleCEOSale plan15,000$92.01$1.4M
Oct 1Heidy King-JonesSee RemarksSale plan28,933$91.03$2.6M
Sep 2Scott L BurrowsCFOSale plan25,732$88.75$2.3M
Sep 2Heidy King-JonesSee RemarksSale plan28,399$87.35$2.5M
Sep 1Cameron TurtleCEOSale plan15,000$87.29$1.3M
Every insider buy and sale for SYRE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SYRE insider trades →

From SEC Form 4 filings by SYRE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SYRE is in one of them and how their past SYRE trades turned out.

SYRE in the AI portfolios
Loading…

SYRE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SYRE in an article yet. Here's the latest on the wider market.

SYRE in the news

About Spyre Therapeutics

Spyre Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops antibody medicines. Its drug candidates are designed to act on the immune system and to last longer between doses, with the aim of treating inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease. The company is also studying its anti-TL1A antibody for rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Its target patients are people living with these chronic immune conditions, and its products are still in development rather than on the market.

Headquarters
Waltham, MA
Founded
2013